Centromere Protein A (CENPA) Regulates Metabolic Reprogramming in the Colon Cancer Cells by Transcriptionally...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• The karyopherin α2 subunit gene (KPNA2) is an oncogene implicated in cancer metabolic reprogramming.
• Understanding KPNA2's role in colon cancer (CC) growth and glycolysis is crucial for targeted therapies.

Purpose of the Study:

• To investigate the function of KPNA2 in colon cancer cell growth and glycolysis.
• To identify upstream regulators of KPNA2 in colon cancer.

Main Methods:

• Bioinformatic screening of the Oncomine database for differentially expressed genes in CC.
• Experimental validation of KPNA2 expression in CC cell lines.
• Assessment of KPNA2 knockdown effects on cell viability, DNA replication, apoptosis, glucose consumption, extracellular acidification rate, and ATP production.
• Identification and validation of Centromere protein A (CENPA) as an upstream activator of KPNA2, involving GCN-5 and H3K27ac modification.

Main Results:

• KPNA2 was found to be highly expressed in colon cancer and CC cell lines.
• Down-regulation of KPNA2 significantly reduced colon cancer cell viability, DNA replication, glucose consumption, extracellular acidification rate, and ATP production, while increasing apoptosis.
• Centromere protein A (CENPA) was identified as an upstream transcription activator of KPNA2, recruiting GCN-5 to the KPNA2 promoter, leading to transcriptional activation.
• Overexpression of CENPA or GCN-5 counteracted the effects of KPNA2 knockdown, restoring growth and glycolysis.

Conclusions:

• The study elucidates a novel regulatory pathway where CENPA recruits GCN-5 to activate KPNA2 transcription.
• Activated KPNA2 enhances colon cancer cell growth and glycolysis, contributing to tumor development.
• This pathway represents a potential therapeutic target for colon cancer treatment.